Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 5, 2013 (14 years ago)

Venlafaxine Hydrochloride Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specifications: Pharmacist complaint of an excessive amount of broken and/or chipped tablets in the bottle.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Venlafaxine Hydrochloride Tablets, 75 mg*, 100-count tablets per bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India; Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-021-01.

Affected NDC 68382-0021-01

Compare with the code on your package — it is the most precise check available.

Drug: Venlafaxine Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Venlafaxine
NDC 68382-0021
HYDROCHLORIDE 75 mg/1 Tablet
Oral
Zydus Pharmaceuticals USA Inc. Rx
Recalling firm
Zydus Pharmaceuticals USA Inc
NDC code
68382-021-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-202-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Venlafaxine recalls

See all
Class II · Moderate risk

Venlafaxine Tablets

Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.

Completed Particulate / foreign matter Zydus Pharmaceuticals (USA) Inc NDC 68382-021-01 D-0310-2025
Class II · Moderate risk

Venlafaxine Hydrochloride

Failed dissolution specifications: out of specification result obtained during routine stability testing for high dissolution.

Terminated Dissolution failure The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7075-61 D-0584-2024
Class II · Moderate risk

Venlafaxine Tablets

Presence of Forein Tablets/Capsules; Venlafaxine Tablets, USP 37.5 mg found in bottles labeled as Venlafaxine Tablets, USP, 50 mg

Terminated Labeling / mix-up Sun Pharmaceutical Industries INC NDC 16714-657-01 D-0703-2021

Other recalls by Zydus Pharmaceuticals USA Inc

All 2013 recalls
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk

Icosapent Ethyl Capsules

Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

Ongoing Failed specification Zydus Pharmaceuticals (USA) Inc D-0400-2026